Ramona Optics raises $25M to scale AI-driven microscopy
What's the deal? Durham, North Carolina-based Ramona OpticsDealroom has a profile for this one. Try Dealroom → has closed an oversubscribed $25 million Series A, led by ARCH Venture Partners. The startup builds advanced microscopes for biopharma and biomedical research.
What's the endgame? Ramona's proprietary multi-camera array microscopy (MCAM) technology is designed for computation rather than the human eye. It captures large, high-definition datasets that AI can then mine for insights.
"For centuries, microscopes have been designed for the human eye," the company said. "Our MCAM technology is built for computation."
Where the money goes: Ramona will direct the funds toward scaling commercial operations, advancing the MCAM technology, expanding on-platform assay capabilities, and building strategic partnerships.
Why now? The round lets Ramona grow beyond a team of roughly 25 employees to meet global demand for its microscopes.
Joining ARCH in the round were Stealthpoint VenturesDealroom has a profile for this one. Try Dealroom →, ND CapitalDealroom has a profile for this one. Try Dealroom →, Fall Line CapitalDealroom has a profile for this one. Try Dealroom →, Hamamatsu VenturesDealroom has a profile for this one. Try Dealroom →, Murchison Capital PartnersDealroom has a profile for this one. Try Dealroom →, and Overlap HoldingsDealroom has a profile for this one. Try Dealroom →.
The signal: Ramona is betting that drug discovery and diagnostics increasingly need statistically meaningful data — many measurements, not just one. Its pitch reflects a wider shift toward pairing imaging hardware with AI to turn observation into quantifiable evidence.
Read more: tradingview.com, biospace.com
Image credit: dave.see
